Selecta Biosciences (SELB) Announces New Preclinical Gene Therapy Data at ASGCT – StreetInsider.com
|
Selecta Biosciences (SELB) Announces New Preclinical Gene Therapy Data at ASGCT
StreetInsider.com “Immunogenicity is a key challenge in gene therapy, limiting the number of diseases and patients that can be effectively treated and presenting a safety hurdle,” said Werner Cautreels, Ph.D., CEO and Chairman of Selecta. “Together with various … |
